0050535
print

Tetanus Antibody, IgG

TETANUS
Example Reports
Not Protected
Protective

Ordering Recommendation

Evaluate the ability of a patient to produce antibody to pure protein vaccine after vaccination to rule out antibody deficiency.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube. "Post" specimen should be drawn 30 days after immunization.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.2 mL) "Pre" and "post" vaccine specimens can be submitted separately or together for testing; if shipped separately, "post" specimen must be received within 60 days of "pre" specimen. Mark specimens clearly as "Pre-Vaccine" or "Post-Vaccine".

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Methodology

Quantitative Multiplex Bead Assay

Performed

Sun-Sat

Reported

1-3 days

Reference Interval

Antibody concentration of > 0.1 IU/mL is usually considered protective.

Interpretive Data

Responder status is determined according to the ratio of a one-month post-vaccination specimen to pre-vaccination concentration of tetanus IgG antibodies as follows:

1.  If the post-vaccination concentration is less than 1.0 IU, the patient is considered a nonresponder.
2.  If the post-vaccination concentration is greater than or equal to 1.0 IU, a patient with a ratio of less than 1.5 is a nonresponder, a ratio of 1.5 to less than 3.0, a weak responder, and a ratio of 3.0 or greater, a good responder.
3.  If the pre-vaccination concentration is greater than 1.0, it may be difficult to assess the response based on a ratio alone.  A post-vaccination concentration above 2.5 IU in this case is usually adequate.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
05/16/2022
X
N/A

CPT Codes

86317

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0050535 Tetanus Antibody, IgG 53935-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Anti-tetanus toxoid IgG
  • C. tetani
  • Clostridium tetani
  • Tetanus Immune Response
  • Tetanus toxoid antibodies
  • Tetanus Vaccine Response
Tetanus Antibody, IgG